Biosimilars – Forecast – Respiratory
In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast period, biosimilars are expected to enter the market and erode patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
